Significantly increased latencies in rotarod performance were recorded in male ALS mice after ApoA1 administration at 16 (p < 0.01) and 17 (p < 0.01) weeks of age, 3- and 4-weeks after treatment, respectively (Figure 1D). Here, APOA1 is linked to amyotrophic lateral sclerosis.